ArticleBMC infectious diseases2025
Clinical, thyroid metabolic, and inflammatory features in pediatric patients with post-acute COVID-19 neuropsychiatric symptoms.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood-Brain Barrier Changes and Related Microvascular Outcomes in Long-COVID: A Comprehensive Review.Life (Basel, Switzerland) · 2026Review
- Long COVID-associated neurological symptoms and brain fog: Understanding the mechanism of neuroinflammation, BBB disruption, diagnostics, and therapeutics.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildren are at increased risk for neuropsychiatric disorders following COVID-19. However, information regarding the clinical, metabolic, and cerebrospinal fluid (CSF) characteristics in patients with neuropsychiatric disorders associated with COVID-19 is limited. In this study, we described the clinical features and retrospectively assessed the metabolic and inflammatory profiles of 13 pediatric patients who exhibited subacute neuropsychiatric symptoms within one month of SARS-CoV-2 infection (NP-COVID-19).
methodsWe retrospectively reviewed and analyzed the clinical and paraclinical data of 13 children with NP-COVID-19 admitted to Qilu hospital from December 15, 2022, to January 31, 2023. Healthy children (HC, n = 21) and pre-pandemic migraine patients (n = 12) were included as controls. Systemic metabolic and inflammatory parameters in NP-COVID-19 patients including thyroid hormone levels and neutrophil-to-lymphocyte ratio were compared with HC. Blood-brain barrier (BBB) integrity and CSF biomarkers of intrathecal inflammation including cytokines and immunoglobulin G index were compared with migraine patients.
resultsCSF SARS-CoV-2 RNA was negative in all patients with NP-COVID-19. No differences in systemic inflammatory parameters were found between NP-COVID-19 patients and HC. However, NP-COVID-19 patients with intact BBB integrity exhibited significantly higher CSF interleukin (IL)-8 levels than migraine controls. In addition, serum free triiodothyronine (FT3) levels were lower in NP-COVID-19 patients than HC and low-T3 syndrome occurred in 61.5% of NP-COVID-19 children.
conclusionsSystemic inflammation rarely occurred in children with NP-COVID-19. Low-T3 syndrome is prevalent in NP-COVID-19 pediatric patients and the neuroinflammatory activation is mainly characterized by elevated CSF IL-8. Further study is required to investigate the pathophysiologic mechanisms in NP-COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.